Skip to main content
. 2020 May 15;112(12):1190–1203. doi: 10.1093/jnci/djaa070

Figure 4.

Figure 4.

Survival in the entire pooled dataset and a pooled subset with known BRCA1/2 mutation status. Estimates of progression-free survival (PFS) and overall survival (OS) from Kaplan-Meier curves, with tests of differences by 2-sided log-rank test. A) PFS and OS in the entire pooled cohort (n = 2636). Kaplan-Meier curves for BRCA1 methylation (orange) and no BRCA1 methylation (grey) curves are depicted. B) PFS and OS in a pooled subset of the entire cohort with known BRCA1/2 mutation status (n = 1248). Kaplan-Meier curves for BRCA1 methylation (orange), BRCA1 mutation (dark blue), BRCA2 mutation (light blue), and BRCA1/2 intact (non–BRCA1-methylated BRCA1/2 wild-type) (grey) curves are depicted. In all graphs, univariate hazard ratios (HR), 95% confidence interval (CI), and P value for BRCA1 methylation vs BRCA1/2 intact, adjusted for study, are given. BRCA1 meth = BRCA1 methylation; non–BRCA1-meth = no BRCA1 methylation.